No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Abatacept |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
2 |
Adalimumab |
Adalimumab |
D02597 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[15] 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
3 |
Ain457 |
- |
- |
- |
- |
[7] 13, 37, 41, 46, 56, 96, 271 |
4 |
Alendronate |
Alendronic acid |
D00939, D07119 |
[1] FDPS |
[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
[7] 19, 41, 46, 50, 271, 274, 299 |
5 |
Alendronate versus alfacalcidol (1-alpha oh vitamin d) |
Alfacalcidol |
D01518 |
[1] VDR |
[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
[3] 41, 46, 50 |
6 |
Alfacalcidol |
Alfacalcidol |
D01518 |
[1] VDR |
[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
[6] 41, 46, 49, 50, 96, 235 |
7 |
Anakinra |
Anakinra |
D02934 |
[2] IL1R1, IL1R2 |
[15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
[15] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
8 |
Anti-thymocyte globulin |
- |
- |
- |
- |
[18] 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
9 |
Baricitinib |
Baricitinib |
D10308 |
[2] JAK1, JAK2 |
[32] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
10 |
Blood samples |
- |
- |
- |
- |
[8] 13, 41, 46, 51, 61, 97, 227, 271 |
11 |
Bosentan |
Bosentan |
D01227, D07538 |
[2] EDNRA, EDNRB |
[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[9] 13, 41, 47, 51, 84, 85, 86, 88, 210 |
12 |
Bosentan mylan |
Bosentan |
D01227, D07538 |
[2] EDNRA, EDNRB |
[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 41 |
13 |
Cnto 136 |
- |
- |
- |
- |
[1] 41 |
14 |
Cortancyl |
Prednisone acetate |
D08416 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[3] 35, 41, 162 |
15 |
Cortancyl ® 1 mg |
Prednisone acetate |
D08416 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
16 |
Cortancyl ® 20 mg |
Prednisone acetate |
D08416 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
17 |
Cortancyl ® 5 mg |
Prednisone acetate |
D08416 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
18 |
Corticoids+ tocilizumab 8mg/kg/4 weeks |
Tocilizumab |
D02596 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[1] 41 |
19 |
Corticosteroid (cs) |
- |
- |
- |
- |
[1] 41 |
20 |
Corticosteroids |
- |
- |
- |
- |
[9] 41, 46, 49, 64, 97, 164, 220, 296, 300 |
21 |
Corticosteroids for systemic use |
- |
- |
- |
- |
[1] 41 |
22 |
Cosentyx |
Secukinumab |
D09967 |
[1] IL17A |
[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
[3] 41, 269, 271 |
23 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[43] 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
24 |
Cyclosporine |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[33] 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
25 |
Dotatate |
Dotatate |
- |
- |
- |
[3] 41, 75, 84 |
26 |
Filgrastim |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[25] 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
27 |
Gevokizumab |
Gevokizumab |
D09911 |
[1] IL1B |
[40] AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
[4] 41, 50, 56, 269 |
28 |
Glucocorticoid treatment |
- |
- |
- |
- |
[1] 41 |
29 |
Glucocorticoids |
- |
- |
- |
- |
[6] 40, 41, 43, 44, 60, 62 |
30 |
Gsk2973327 |
- |
- |
- |
- |
[1] 41 |
31 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
[18] 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
32 |
Infliximab |
Infliximab |
D02598 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[22] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
33 |
Kevzara ® |
Sarilumab |
D10161 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[1] 41 |
34 |
Kineret |
Anakinra |
D02934 |
[2] IL1R1, IL1R2 |
[15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
[5] 41, 49, 65, 266, 299 |
35 |
Kpl-301 |
- |
- |
- |
- |
[1] 41 |
36 |
Mavrilimumab |
Mavrilimumab |
D09930 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[2] 41, 46 |
37 |
Methotrexate |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
38 |
Methotrexate treatment |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 41 |
39 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[36] 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
40 |
Metoject |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[2] 41, 46 |
41 |
Naltrexone |
Naltrexone |
D02095, D05113 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
42 |
Naltrexone hydrochloride |
Naltrexone |
D02095, D05113 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[7] 10, 40, 41, 42, 43, 44, 45 |
43 |
Nivolumab |
Nivolumab |
D10316 |
[1] PDCD1 |
[3] Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
[10] 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
44 |
Over encapsulated prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
45 |
Pet10 |
- |
- |
- |
- |
[1] 41 |
46 |
Pet3 |
- |
- |
- |
- |
[1] 41 |
47 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[38] 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
48 |
Prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[43] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
49 |
Prednisone and ustekinumab treatment |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[1] 41 |
50 |
Prednisone capsules |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
51 |
Prednisone tablets usp, 1 mg |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[2] 41, 46 |
52 |
Prednisone tablets usp, 2.5 mg |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
53 |
Prednisone tablets usp, 5 mg |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[2] 41, 46 |
54 |
Prednisone tablets, usp |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[3] 41, 43, 44 |
55 |
Prednisone therapy and pharmacokinetic |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
56 |
Prednisone treatment |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 41 |
57 |
Ro 001-9265/f02 |
- |
- |
- |
- |
[1] 41 |
58 |
Ro 001-9265/f03 |
- |
- |
- |
- |
[1] 41 |
59 |
Ro 001-9265/f04 |
- |
- |
- |
- |
[1] 41 |
60 |
Ro 487-7533/f10-04 |
- |
- |
- |
- |
[4] 41, 46, 51, 107 |
61 |
Roactemra |
- |
- |
- |
- |
[5] 41, 46, 51, 86, 107 |
62 |
S78989 |
- |
- |
- |
- |
[3] 41, 50, 56 |
63 |
Sar153191 |
Sarilumab |
D10161 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[4] 41, 46, 107, 271 |
64 |
Sarilumab |
Sarilumab |
D10161 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[4] 41, 46, 84, 107 |
65 |
Sarilumab sar153191 |
Sarilumab |
D10161 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[1] 41 |
66 |
Secukinumab |
Secukinumab |
D09967 |
[1] IL17A |
[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
[7] 13, 37, 41, 46, 160, 269, 271 |
67 |
Secukinumab 300 mg, s.c. |
Secukinumab |
D09967 |
[1] IL17A |
[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
[1] 41 |
68 |
Sirukumab |
Sirukumab |
D10080 |
[1] IL6 |
[46] AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection |
[2] 41, 46 |
69 |
Tocilizumab |
Tocilizumab |
D02596 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
70 |
Tocilizumab + glucocorticoids (gcs) |
Tocilizumab |
D02596 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[1] 41 |
71 |
Tocilizumab sc |
Tocilizumab |
D02596 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[3] 41, 46, 107 |
72 |
Tocilizumab treatment |
Tocilizumab |
D02596 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[1] 41 |
73 |
Treatment |
- |
- |
- |
- |
[1] 41 |
74 |
Upadacitinib |
Upadacitinib |
D10994 |
[1] JAK1 |
[26] EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
[6] 41, 46, 49, 96, 97, 271 |
75 |
Ustekinumab |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[15] 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
76 |
Vitamin d |
Vitamin d |
- |
- |
- |
[18] 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
77 |
Xoma 052 |
- |
- |
- |
- |
[5] 41, 46, 50, 56, 106 |